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Introduction
 Hepatitis B virus (HBV) is one of the major causes of 
liver disease worldwide, and chronic HBV infection can 
progress to cirrhosis and hepatocellular carcinoma .About 
5% of the global population (350 million persons), are 
currently infected with HBV (Elefsiniotis et al., 2005).
Chronic HBV can be treated with a nucleoside analogue, 
lamivudine, which in the short term can inhibit HBV 
replication by blocking the viral polymerase activity. 
However, during long term treatment, lamivudine resistant 
strains have been detected. Based on a previous study, 
this resistance has been associated with variations in 
the YMDD motif of the HBV polymerase which is the 
catalytic site (Degertekin et al., 2009) and after some study 
on this part of gene we designed our primers and probes 
for amplification. Lamivudine resistant HBV strains with 
YMDD mutations are an important factor for the failure of 
chronic hepatitis B treatment. Some patients with mutation 
even went worse, and eventually died. However, it has 
been rarely reported whether YMDD mutations have 
natural existence (Geng et al., 2006).
 Treatment with lamivudine leads to the development 
of lamivudine-resistant virus which is associated with a 
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Abstract
 HBV infection is a contagious disease that may transmit vertically or horizontally by blood products and 
body secretions. Over 50% of Iranian carriers have contracted the infection prenatally, making this the most 
likely route of transmission of HBV in Iran. This study assesses the resistance to Lamivudine in patients with 
chronic Hepatitis B infection using ZNA probe Real Time PCR new method. To evaluate the effectiveness of 
Lamivudine therapy in patients with chronic hepatitis B infection, a study was conducted on 70 patients (63 men 
and 7women), who had received in first line Lamivudine. All patients were tested for the presence of HBsAg, 
HBeAg, serum ALT level and HBV DNA load before and after treatment with Lamivudine .in all of samples 
resistance to Lamivudine were tested with ZNA Probe Real Time PCR method. Our results show that ZNA Probe 
Real Time PCR method could detect wild type,YMDD, and its mutants, tyrosine-isoleucine-aspartate-aspartate 
and tyrosine-valine-aspartate-Aspartate. Among an estimated seventy patients with chronic hepatitis B infection, 
18 (25.7%) were resistant to lamivudine. Only one patient was Negative for presence of HBS-Ag (5.6%) and 
two patients were negative for HBe-Ag (11.1%) .The real-time PCR with Zip nucleic acid probes is a sensitive, 
specific and rapid detection method for mutations at the YMDD motif, which will be essential for monitoring 
patients undergoing lamivudine antiviral therapy.  
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gradual reversal of the drug’s antiviral effects as early 
as the first year of therapy. This resistance is shown 
with increased HBV DNA concentrations and HBeAg- 
positivity and/or increased alanine transaminase (ALT) 
concentrations (Zhou et al., 2012) and in the same way in 
our study the patients had shown these variations. During 
lamivudine therapy, for those patients with persistently 
elevated ALT and HBV DNA concentrations it is vital to 
determine the presence of lamivudine resistant mutations. 
Detection of drug resistance mutation is recommended for 
rapid identification and effective treatment monitoring 
before HBV DNA and ALT concentrations increase (Wu 
et al., 2012). In Islamic Republic of Iran (I.R. Iran), recent 
studies reported the range of HBV infection between 
1.2 to 9.7 percent in different regions. Generally, it is 
estimated that about 1.5 to 2.5 million people are suffering 
from HBV infection in I.R. Iran, and some of them are 
carriers who may transmit infection to others (Fallahian 
et al., 2010). HBV exhibits a mutation rate more than 10-
fold higher than other DNA viruses. The replication and 
mutation rate is an important factor in the viral diversity. 
HBV uses a reverse transcription step in its replication 
cycle and the rate of evolution in the range of 104-105 
nucleotide substitutions per site per year is shown (Kamar 
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et al., 2004).The main aim of therapy of chronic hepatitis 
B is to achieve a sustained suppression of HBV replication, 
to obtain remission of the underlying liver disease and 
thus prevent its progression towards cirrhosis and HCC 
(Brunelle et al., 2005). Continuous viral suppression is 
equally essential in order to avoid the risk of the emergence 
of antiviral resistance (Buti et al., 2007). Consequently, 
patients should be considered for antiviral treatment only 
when (a) serum HBV DNA is above 2,000 IU/ml (that is, 
approximately 10,000 copies/ml), and/or (b)serum ALT 
levels are above the upper limit of normal(ULN), and (c) 
liver biopsy shows moderate to severe active inflammation 
and/or fibrosis using a standardized scoring system (e.g. 
≥A2 and/or ≥F2 when using the METAVIR score) (Kamar 
et al., 2004). Many current therapeutic approaches for 
treating HBV infection focus on the DNA polymerase as 
a target to inhibit viral replication, including nucleoside 
analogs that terminate viral DNA synthesis and decrease 
viral load in most cases (Rizzetto et al., 2005). Resistance 
to lamivudine, is invariably associated with mutations in 
the highly conserved YMDD motif, which is part of the 
catalytic site of the HBV polymerase(Arslan et al., 2008). 
Many methods were developed to detect LAM-resistant 
mutations, such as direct polymerase chain reaction 
(PCR) sequencing, INNO-LiPA, restriction fragment 
length polymorphism (PCR-RFLP), matrix-assisted laser 
desorption/ionization time of fight-mass spectrometry 
(MALDI TOF MS) with their respective advantages and 
disadvantages (Moosavy et al., 2011). Sequencing remains 
the best approach to the identification of new mutations. 
However, it cannot detect total mutations in less than 25% 
of total viral population and is not appropriate for large-
scale use in large cohort studies or clinical laboratories 
because of  its labor intensive and time consuming 
(Aghasadeghi et al., 2011). Manipulations INNO-LiPA 
and MALDI TOF MS are capable to detect variants, 
but more strict experiment conditions and equipment’s 
are required. PCR-RFLP could only detect mutations in 
a high proportion and is also labor intensive and time 
consuming (Aberle et al., 2001). Monitoring of viral 
load will play an important role in assessing treatment. 
Prolonged treatment with antiviral agents can lead to the 
emergence of drug-resistant virus (Chen et al., 2010). Zip 
nucleic acids (ZNAs) are oligonucleotides conjugated 
with cationic spermine units which increase affinity for 
their target by decreasing electrostatic repulsion between 
negatively charged anionic single strand Nucleic Acids to 
improve hybridization, thus enhancing and accelerating 
target recognition (Noir et al., 2008). The possibility of 
modulating the global charge of the ZNA oligonucleotide-
oligocation conjugates by the number of cationic spermine 
moieties attached to the Nucleic Acid oligomer, is a key 
to predict melting temperature of ZNA-DNA/ZNA-RNA 
hybrids easily. Tm increases linearly with the length of 
the oligocation.ZNAs were shown to enable specific 
and sensitive reactions when used as primers for PCR 
and Reverse Transcription. Moreover ZNA probes 
provide broad flexibility in assay design and represent an 
effective alternative to Minor Groove Binder (MGB) and 
Locked Nucleic Acid (LNA) containing oligonucleotides 
(Voirin et al., 2007). Lamivudine resistance is associated 
with increased HBV DNA concentrations and HBeAg-
Positivity and increased alanine transaminase (ALT)
concentrations with exacerbation of liver disease during 
treatment (Li et al., 2005). Thus, detection of mutant 
resistant to treatment is necessary to prevent disease 
progression and malignancy and recommended for 
rapid identification and sensitive treatment monitoring 
(Fasano et al., 2012). In this study described a sensitive 
method for detection of LAM-resistant mutants by Real-
time fluorescent quantitative PCR using ZNA-probes 
in Chronic HBV patients  who had been long-term 
lamivudine monotherapy in Kerman, southeast of Iran. 
So far no study has been done in this area with same 
method. This method can be used to detect YMDD and its 
mutants, tyrosine-isoleucine-aspartate-aspartate (YIDD) 
and tyrosine-valine-aspartate-aspartate (YVDD) in a 
single multiplex reaction simultaneously.
Materials and Methods
Patients
 In retrospective study, Seventy patients (63 men and 
7 women, mean age=44 years, range 41-66 years) who 
were diagnosed as Chronic Hepatitis B infection(CHB)
from October 2010 to December 2011 in our Laboratory 
(Virology Laboratory of the Besat Specialist Clinic, 
Kerman, IRAN) following the guidelines of prevention 
and treatment of chronic hepatitis B were enrolled in 
this study. The decision to treat is primarily based on the 
combination of three criteria: a) serum HBV DNA levels, 
b) serum alanine amino transferase (ALT) levels and c) 
histological grade and stage of the underlying liver disease. 
Exclusion criteria included a coexisting severe illness, 
organ or bone marrow transplantation, recent treatment 
with systemic corticosteroids, immunosuppressant’s or 
chemotherapeutic agents, liver disease not due to hepatitis 
B, and seropositivity for human immunodeficiency virus 
(HIV) or hepatitis C (HCV) or hepatitis D virus.
Serological tests
 The blood from the patients with chronic hepatitis 
B was assayed for alanine transaminase at our clinical 
laboratory using an automated analyzer. HBsAg and 
HBeAg as well as Anti-HCV and Anti-HIV were 
determined using commercial radioimmunoassay kits 
(Abbott Laboratories, Chicago, IL). Hepatitis D antigen 
was detected using enzyme immunoassay kits (Abbott 
Laboratories, Chicago, IL). 
HBV DNA level
 5 ml of peripheral blood were collected from each 
patient into EDTA-containing vacutainer tubes. Plasma 
was separated and stored at -70°C .HBV DNA was 
extracted from 200 μL of plasma with High Pure Viral 
Nucleic Acid kit (Roche Diagnostics GmbH, Mannheim, 
Germany). Serum HBV-DNA levels were quantified 
via quantitative Real-time polymerase chain reaction 
with a commercial detection kit (artus HBV kit, Qiagen, 
Germany). The Real-time PCR had a lower limit of 35 
Asian Pacific Journal of Cancer Prevention, Vol 13, 2012 3
Detection of HBV Resistance to Lamivudine in Patients with Chronic 
Hepatitis B, Using Zip Nucleic Acid Probes, Kerman, Southeast of Iran
0
25.0
50.0
75.0
100.0
N
ew
ly
 d
ia
gn
os
ed
 w
ith
ou
t 
tr
ea
tm
en
t 
N
ew
ly
 d
ia
gn
os
ed
 w
ith
 t
re
at
m
en
t 
Pe
rs
is
te
nc
e 
or
 r
ec
ur
re
nc
e
Re
m
is
si
on
N
on
e
Ch
em
ot
he
ra
py
Ra
di
ot
he
ra
py
Co
nc
ur
re
nt
 c
he
m
or
ad
ia
tio
n
10.3
0
12.8
30.025.0
20.310.16.3
51.7
75.0
51.1
30.031.3
54.2
46.856.3
27.625.0
33.130.031.3
23.7
38.0
31.3
Table 1. Baseline Characteristics of Patients
Characteristics Male Female Total
Gender (%)  63 (90%)  7 (10%) 70 (100%) 
Mean age (years)   43±8   41 ±9  42±8.5 
HBeAg-Positive (%)  30 (47.6%)  1 (14.2%)  31 (44.2%) 
F3–F4 (%) (Classified by liver biopsy examination or clinical radiological 
findings) 12 (19%) 0 (%) 12 (17.1%)
Cirrhosis (%)  3 (4.7 %)  0 (%)  3 (4.28%)
Prior lamivudine therapy (%)
 63 (100%)  7 (100%)  70 (100%)
Lamivudine resistance (%)
 17 (26.9%) 1 (14.2%) 18 (25.7%) 
Mean ALT (IU/L)   320±15  300±10  310 ± 12 
Mean HBV-DNA (log10 IU/mL)
  10±2.1  7±1.3  8.5 ± 1.7
copies/mL.
Detection of YMDD mutations
 Determination of LAM resistance was done with 
specific primers and probes from the HBV polymerase 
region in YMDD motif  that were design by Dr Mollaie 
Using Beacon designer software (Version 8 Primer, 
Biosoft, USA ).Primers and probes synthesized  by 
Metabion company (metabion international AG, Germany 
). All of samples were tested with Real Time ZNA probe 
method, which has been developed for detection of 
lamivudine- resistant mutants in our laboratory, and this 
is a patent test for us. 5 µl of DNA sample combined 
with 15 µl reaction mixture of fermentas TaqMan Master 
mix (Thermo fisher Scientific, USA) contain primers and 
probe were subjected to Real-time PCR. The condition 
for the ZNA mediated probe assay was initially 10 min 
with hot start Taq DNA polymerase at 95°C followed by 
45 cycles at 95°C for 15 sec and 60°C for 40 sec. Of each 
cycle at the extension step, the fluorescent signals of Probe 
YMDD, YVDD, YSDD and Probe YIDD were measured 
at Green, Yellow, Orange and Red channel, respectively. 
All of samples also were tested via quantitative Real Time 
PCR with a commercial Lamivudine Resistance HBV 
detection kit (Bioproducts, Mag. Th. Langmann GmbH). 
Quantitative determination of the amplified products 
was done with the Rotor Gene 6000 (Corbett Research, 
Australia).
Statistical analyses
 Chi square and Fisher’s exact Tests were used to 
analyze the data obtained by SPSS 11.5 software (SPSS 
Inc, Chicago; USA). The differences or association with 
p<0.05 were considered statistically significant.
Results 
 Seventy patients with CHB were selected during about 
one year (2010-2011) who were  treated with lamivudine 
as the first drug for 30-86 weeks (Mean= 64 weeks).
Eighteen (25.7%) of whom developed LAM resistance 
mutations who six experienced virological relapse after 
discontinuation of LAM treatment. Of the seventy samples 
Sixty-one percent of patients were HBeAg Positive. Liver 
biopsy was available in 23 patients and 12 (52%) of them 
showed grade 3-4 fibrosis stage. Because the study was on 
patients who their sample had been previously collected, 
all liver biopsy samples were not available. Additionally, 
three patients without liver biopsy had been classified as 
having cirrhosis based on clinical, analytical and ultra 
sonographic findings. Thus, 15 (21.4%) of 70 patients were 
classified as having severe fibrosis or cirrhosis. Mean ALT 
level was 485.4±28.7 IU/L and mean HBV-DNA level 
was 8.311±0.269 log 10 IU/mL (Table 1). Three types of 
lamivudine resistance in these samples were determined, 
Nine patients had a YIDD mutation (50%),Two patients 
had a YSDD mutation (11.1%) and seven patients had a 
YIDD/YVDD mix mutation (38.9%). Serological and 
pathological details of the eighteen patients are shown in 
Figure 2. ALT level and HBV DNA Load were measured 
in two stages, before and after treatment with Lamivudine. 
Figure 3. Histogram Results of ALT and HBV DNA 
Load, Before and After Treatment with Lamivudine.
Figure 1. Results of ZNA Probes in Four Channels and 
YIDD/YVDD Mix Mutations.
Figure 2. Serological and Pathological Details of the 
Eighteen Patients.
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Statistical calculations on the seventy samples showed 
that there is a significant relationship between gender and 
drug resistance to lamivudine. (P Value=0.01).Histogram 
results of ALT and DNA HBV load, before and after 
treatment with Lamivudine is compared and is shown in 
the Figure 3. To evaluate the real-time PCR using ZNA 
mediated probe, each DNA template and each probe were 
paired in separate reactions, for example using YMDD 
template with Probe and primers for YMDD. Signals 
were showed but not matched the respective template/
probe pair and it represents either non-specific reactions or 
cross reactions between probes and templates. If the signal 
only appears when probe and template match, it ensures 
the probe is specific for its template. All samples were 
typed blindly to each variant by standard Real Time PCR 
kit, without any conscious bias. There was no difference 
between the results of two methods (Figure 4).
Discussion
To date, many assays have been used for detection of 
lamivudine-resistant mutants in patients with Hepatitis 
B. Differences in sensitivity, specificity, cost, and time 
required, exist in these methods(Liu et al., 2011). Real-
time PCR is able to quantitatively detect a small portion 
of resistant mutants in HBV populations and ZNA probe 
detection method is a newly developed method for 
detection of low abundant mutants in the background 
of wild-type HBV (Liu et al., 2010). So we used these 
methods and we could detect single mutation about YSDD 
and YIDD. Interestingly we reported YIDD, YSDD and 
YVDD mutations. Another thing which was mentioned 
is gender. In our study most of drug resistance cases were 
in men. Sequence analysis, on the other hand, has already 
proven to be a useful technique for mutation detection, 
however, it takes more time and cannot be used everywhere 
and also cannot detect any mixtures of variant and wild 
type virus (Aberle et al., 2001) but sequencing results of 
this study were same to lamivudine detection kit which 
used in this study and PCR-RFLP (Data not shown). Using 
ZNA probe method is quick and inexpensive comparing to 
other probe methods for detection of YMDD mutation; and 
ZNA probe method is more trustable than other methods. 
The results obtained with both methods were completely 
concordant in all serum samples. ZNA was able to detect 
as low as 35 copies/mL of YMDD mutants, while other 
method only detected 1000 copies/mL of YMDD Mutants. 
In addition, the cost of ZNA is slightly lower and is much 
more rapid so it requires less manual work than PCR-
RFLP. The total assay time for ZNA real-time PCR was 
1.5 hours, respectively. Another advantage of the real-time 
PCR method is it is able to calculate the ratio of mutants to 
total virus in samples. This will be useful in clinical studies 
on the dynamics of resistant mutants during lamivudine 
therapy.In the current study, the rate of YMDD mutations 
was 25.7% after two year of lamivudine treatment, which 
is higher than in a previous study. However, it is lower 
than that in another study, which had YMDD mutations 
in 57.4% of Japanese patients with chronic hepatitis B 
after one year of lamivudine treatment. The current study 
also aimed to determine the association of pretreatment 
HBV-DNA levels and HBeAg status at baseline with the 
occurrence of YMDD mutations. Logistic regression 
analysis demonstrated that high pretreatment HBV-
DNA levels are independent factors for the occurrence 
of YMDD mutations. These findings are in accordance 
with the results of other studies (Amini-Bavil-Olyaee et 
al., 2008). HBeAg status at baseline is recognized as an 
independent factor for YMDD mutations. Thus HBeAg 
status at baseline is one of the predictors (Fasano et 
al., 2012). But the results are not consistent with those 
of another study suggesting that the rate of YMDD 
mutations in HBeAg positive patients was similar to that 
in HBeAg negative patients. The present study suggests 
that pretreatment HBV-DNA levels and HBeAg status 
should be considered for patients with chronic HBV after 
lamivudine treatment. High ALT levels are thought to be 
related to a more rapid selection of YMDD mutations. The 
current study revealed no significant differences in ALT 
levels in patients with or without YMDD mutations prior 
to lamivudine treatment. Logistic regression analysis in 
our study also showed that pretreatment ALT levels are 
not predictors of YMDD mutations. Studies including the 
current one showed that high ALT levels are not related 
to the rapid selection of YMDD mutations .Thus, there 
are different findings concerning the correlation of ALT 
levels with YMDD mutations. However, ALT levels are 
very important parameters for host factors, and they should 
be monitored carefully during lamivudine treatment. In 
conclusion, virological and biochemical markers (HBeAg, 
HBV DNA load, and serum ALT level) are used in the 
diagnosis and monitoring of HBV disease. A combined 
end point of biochemical response (ALT normalization) 
and virologic (serum HBV-DNA suppression) response 
is used frequently. In this study, of seventy patients, 
thirty eight (54.2%) was HBeAg negative. We did not 
study other markers include liver covalently closed 
circular DNA (cccDNA) , HBV genotype, and genotypic 
resistance markers. Also, lack of define of a target serum 
HBVDNA level, and different assays for a patient to make 
the interpretation difficult. We calculated the amount of 
mutations according to rise of serum HBVDNA titer or 
ALT level and showed it in some divided times. However, 
in many clinical trials, resistance is calculated by about 
the cumulative probability of HBV polymerase mutations. 
In present study, most chronic hepatitis B patients on 
lamivudine treatment developed mutations in mean 36±10 
months. In CHB patients without YMDD mutation and 
high HBVDNA titer, analysis for possible new mutants 
should be performed. Elevated HBVDNA titer might be 
supposed as a clue to drug resistant, regardless of ALT 
level or mutation report. The YMDD-motif mutations 
can occur spontaneously with a fairly high incidence 
in CHB patients untreated with lamivudine or adefovir. 
These mutations might be the result of accumulated 
base mismatch caused by viral polymerase. More basic 
and clinical studies are needed to clarify the influence 
of YMDD mutations in hepatitis B progression and 
antiviral treatment. Lamivudine therapy would increase 
the risk of mutations 5.23 times higher than the untreated 
patients. A higher HBV DNA copy number was associated 
with higher incidence of natural YMDD mutation. No 
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